Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
about
Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of ChildrSerious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.
P2860
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Disease status, reasons for di ...... hritis treated with etanercept
@en
Disease status, reasons for di ...... ritis treated with etanercept.
@nl
type
label
Disease status, reasons for di ...... hritis treated with etanercept
@en
Disease status, reasons for di ...... ritis treated with etanercept.
@nl
prefLabel
Disease status, reasons for di ...... hritis treated with etanercept
@en
Disease status, reasons for di ...... ritis treated with etanercept.
@nl
P2093
P2860
P50
P1476
Disease status, reasons for di ...... hritis treated with etanercept
@en
P2093
Achille Marino
Adele Civino
Alberto Martini
Alessandro Consolaro
Alessandro De Fanti
Alma Nunzia Olivieri
Angelo Ravelli
Chiara Sandrin
Claudia Fede
Denise Pires Marafon
P2860
P2888
P356
10.1186/S12969-016-0126-0
P577
2016-12-20T00:00:00Z
P6179
1038678836